PKO Investment Management Joint-Stock’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.21M | Sell |
21,000
-2,000
| -9% | -$115K | 0.09% | 158 |
|
|
2026
Q1 | $1.39M | Sell |
23,000
-3,000
| -12% | -$175K | 0.12% | 137 |
|
|
2025
Q4 | $1.4M | Sell |
26,000
-2,500
| -9% | -$120K | 0.11% | 143 |
|
|
2025
Q3 | $1.29M | Hold |
28,500
| – | – | 0.11% | 133 |
|
|
2025
Q2 | $1.32M | Buy |
28,500
+16,500
| +138% | +$810K | 0.14% | 113 |
|
|
2025
Q1 | $732K | Sell |
12,000
-4,000
| -25% | -$233K | 0.08% | 145 |
|
|
2024
Q4 | $905K | Sell |
16,000
-4,000
| -20% | -$223K | 0.11% | 111 |
|
|
2024
Q3 | $1.03M | Hold |
20,000
| – | – | 0.13% | 104 |
|
|
2024
Q2 | $831K | Hold |
20,000
| – | – | 0.1% | 123 |
|
|
2024
Q1 | $1.09M | Sell |
20,000
-14,000
| -41% | -$713K | 0.13% | 116 |
|
|
2023
Q4 | $1.74M | Hold |
34,000
| – | – | 0.22% | 77 |
|
|
2023
Q3 | $1.97M | Hold |
34,000
| – | – | 0.27% | 61 |
|
|
2023
Q2 | $2.17M | Buy |
34,000
+11,000
| +48% | +$738K | 0.27% | 66 |
|
|
2023
Q1 | $1.59M | Hold |
23,000
| – | – | 0.21% | 87 |
|
|
2022
Q4 | $1.65M | Buy |
23,000
+1,000
| +5% | +$75.4K | 0.24% | 76 |
|
|
2022
Q3 | $1.56M | Sell |
22,000
-2,000
| -8% | -$145K | 0.27% | 70 |
|
|
2022
Q2 | $1.85M | Sell |
24,000
-1,000
| -4% | -$76.2K | 0.27% | 74 |
|
|
2022
Q1 | $1.83M | Sell |
25,000
-30,000
| -55% | -$2.01M | 0.22% | 79 |
|
|
2021
Q4 | $3.43M | Buy |
55,000
+25,599
| +87% | +$1.5M | 0.39% | 59 |
|
|
2021
Q3 | $1.74M | Hold |
29,401
| – | – | 0.21% | 81 |
|
|
2021
Q2 | $1.96M | Hold |
29,401
| – | – | 0.25% | 65 |
|
|
2021
Q1 | $1.86M | Hold |
29,401
| – | – | 0.3% | 52 |
|
|
2020
Q4 | $1.82M | Hold |
29,401
| – | – | 0.31% | 51 |
|
|
2020
Q3 | $1.77M | Hold |
29,401
| – | – | 0.34% | 53 |
|
|
2020
Q2 | $1.73M | Hold |
29,401
| – | – | 0.39% | 50 |
|
|
2020
Q1 | $1.64M | Hold |
29,401
| – | – | 0.56% | 42 |
|
|
2019
Q4 | $1.89M | Buy |
29,401
+11,157
| +61% | +$639K | 0.47% | 50 |
|
|
2019
Q3 | $925K | Hold |
18,244
| – | – | 0.23% | 66 |
|
|
2019
Q2 | $827K | Hold |
18,244
| – | – | 0.21% | 68 |
|
|
2019
Q1 | $870K | Hold |
18,244
| – | – | 0.23% | 70 |
|
|
2018
Q4 | $948K | Hold |
18,244
| – | – | 0.27% | 62 |
|
|
2018
Q3 | $1.13M | Hold |
18,244
| – | – | 0.23% | 58 |
|
|
2018
Q2 | $1.01M | Sell |
18,244
-5,697
| -24% | -$308K | 0.21% | 65 |
|
|
2018
Q1 | $1.51M | Hold |
23,941
| – | – | 0.34% | 50 |
|
|
2017
Q4 | $1.47M | Buy |
23,941
+2,944
| +14% | +$184K | 0.37% | 52 |
|
|
2017
Q3 | $1.34M | Buy |
20,997
+7,867
| +60% | +$459K | 0.36% | 50 |
|
|
2017
Q2 | $732K | Buy |
13,130
+7,651
| +140% | +$416K | 0.25% | 54 |
|
|
2017
Q1 | $298K | Buy |
+5,479
| New | +$301K | 0.14% | 62 |
|
Other funds holding BMY
MGP
PKO Investment Management Joint-Stock's BMY Position: Q2 2026 in Review
PKO Investment Management Joint-Stock reduced its Bristol-Myers Squibb (BMY) stake by 8.7% in Q2 2026, selling an estimated $115K and leaving 21,000 shares worth $1.21M. The position accounts for 0.09% of the portfolio, ranked #158.
PKO Investment Management Joint-Stock first reported a position in BMY in Q1 2017 and has held it in 38 quarters since. The position peaked at $3.43M in Q4 2021. 1,433 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- PKO Investment Management Joint-Stock held 21,000 shares of Bristol-Myers Squibb worth $1.21M as of Q2 2026.
- PKO Investment Management Joint-Stock sold 2,000 Bristol-Myers Squibb shares in Q2 2026, an estimated $115K.
- Bristol-Myers Squibb made up 0.09% of PKO Investment Management Joint-Stock's portfolio in Q2 2026, its #158 holding.
- PKO Investment Management Joint-Stock first reported a position in Bristol-Myers Squibb in Q1 2017 and has held it in 38 quarters since.
- PKO Investment Management Joint-Stock's Bristol-Myers Squibb position peaked at $3.43M in Q4 2021.
- 1,433 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on PKO Investment Management Joint-Stock's 13F filing for Q2 2026, filed 20 Jul 2026.